• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Envoy Medical Inc.

    4/18/25 4:19:07 PM ET
    $COCH
    Industrial Specialties
    Health Care
    Get the next $COCH alert in real time by email
    DEFA14A 1 ea0238213-04.htm DEFINITIVE ADDITIONAL MATERIALS

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ––––––––––––––––––––––––––––––––––

    SCHEDULE 14A

    ––––––––––––––––––––––––––––––––––

    Proxy Statement Pursuant to Section 14(a) (Rule 14a-101) of the
    Securities Exchange Act of 1934

    Filed by the Registrant

     

    ☒

    Filed by a Party other than the Registrant

     

    ☐

    Check the appropriate box:

    ☐

     

    Preliminary Proxy Statement

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

    Definitive Proxy Statement

    ☒

     

    Definitive Additional Materials

    ☐

     

    Soliciting Material Pursuant to §240.14a-12

    Envoy Medical, Inc.
    (Name of Registrant as Specified in its Charter)

    –––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

     

    No fee required.

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

      

     

     

    CONTROL ID:

    REQUEST ID:

     

    ENVOY MEDICAL, INC

       
               

    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
    for the Annual Meeting of Stockholders

     

    DATE:

    Wednesday, May 28, 2025

     
     

    TIME:

    3:00 PM Central Time

       
     

    LOCATION:

    Fairfield Inn & Suites, 1125 Co Rd E East, Vadnais Heights,
    MN 55110

               

    HOW TO REQUEST PAPER COPIES OF OUR MATERIALS

    PHONE: 
    Call toll free 
    1-866-752-8683

    FAX: 
    Send this card to 
    202-521-3464

    INTERNET:
    https://www.iproxydirect.com/Coch
    and follow the on-screen
    instructions
    .

    EMAIL:
    [email protected]
    Include your Control ID in your
    email.

               

    This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.iproxydirect.com/COCH

    If you want to receive a paper copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request, as instructed above, before May 14, 2025.

    you may enter your voting instructions at https://www.iproxydirect.com/COCH
    until 11:59 pm eastern time May 27, 2025.

       

    The purposes of this meeting are as follows:

    1.     To elect two Class II director nominees named in the Proxy Statement to the Envoy Medical Board of Directors, to serve until the earlier of the 2028 annual meeting of stockholders, the election of such director’s successor, or such director’s death, resignation or removal;

    2.     To ratify the appointment of Grant Thornton LLP as Envoy Medical’s independent registered public accounting firm for the year ending December 31, 2025;

    3.     To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation;

    4.     To approve an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan; and

    5.     to transact such other business as may properly come before the annual meeting or any adjustment thereof.

    Pursuant to Securities and Exchange Commission rules, you are receiving this Notice that the proxy materials for the Annual Meeting are available on the Internet. Follow the instructions above to view the materials and vote or request printed copies.

    The board of directors has fixed the close of business on April 10, 2025 as the record date for the determination of stockholders entitled to receive notice of the Annual Meeting and to vote the shares of our Class A common stock, par value $0.0001 per share, they held on that date at the meeting or any postponement or adjournment of the meeting.

    The Board of Directors recommends that you vote ‘for’ all proposals above.

    Please note — This is not a Proxy Card — you cannot vote by returning this card

     

           
             

    ENVOY MEDICAL, INC
    SHAREHOLDER SERVICES
    1 Glenwood Ave Suite 1001
    Raleigh NC 27603

         

    FIRST-CLASS MAIL  
    US POSTAGE
    PAID
    RALEIGH NC
    PERMIT # 870

             
             
             

    Time Sensitive shareholder information enclosed

       
             
             
             
             
             
             
             
             
             

    IMPORTANT SHAREHOLDER INFORMATION

           
             

    your vote is imporant

           
             
             
             
             
             
             
             
             
             
             
             

    ENVOY MEDICAL, INC
    SHAREHOLDER SERVICES
    1 Glenwood Ave Suite 1001
    Raleigh NC 27603

         

    FIRST-CLASS MAIL  
    US POSTAGE
    PAID
    RALEIGH NC
    PERMIT # 870

             

    Time Sensitive shareholder information enclosed

     

    IMPORTANT SHAREHOLDER
    INFORMATION

    your vote is imporant

     

    Get the next $COCH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COCH

    DatePrice TargetRatingAnalyst
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    More analyst ratings

    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial

      White Bear Lake, Minnesota--(Newsfile Corp. - May 13, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announces achieving the important milestone of successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. Brent Lucas, CEO of Envoy Medical commented: "We are excited to report the positive and meaningful progress of our pivotal clinical trial, which is currently on track and moving along as anticipated. We are optimistic we will be able to expand the study

      5/13/25 9:15:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Reports on First Quarter 2025 Results

      Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

      5/1/25 4:30:00 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • EdgarAgents Debuts EA34 Plugin at Centri Capital Conference to Simplify and Expedite Financial Filing Process for Mid-to-Microcap Companies

      NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- EdgarAgents (EA), a leading provider of simplified and efficient solutions that expedite U.S. Securities and Exchange Commission (SEC®) compliance filings, announces today the availability of EA34 Plugin, the company's newest user-centered technology-enabled solution. EA34 Plugin officially launches at the Centri Capital Conference in New York City at Nasdaq Global Headquarters. Powered by the latest inline eXtensible Business Reporting Language (iXBRL) — a global standard to share financial and business data electronically — and EDGAR® technology, EA34 Plugin was tailor-made as a "hybrid-service" financial content management collaboration pla

      4/22/25 6:00:00 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Taylor Glen A

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      3/13/25 4:06:56 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Kantor Susan acquired 34,705 shares, increasing direct ownership by 80% to 77,887 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      12/26/24 5:52:27 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Large owner Anzu Spac Gp I Llc converted options into 1,028,986 shares and disposed of 2,028,986 shares (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      12/26/24 5:39:35 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Leadership Updates

    Live Leadership Updates

    See more
    • Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

      WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

      6/11/24 8:00:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical to Host Fireside Chat Event December 7

      Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company

      12/4/23 8:15:00 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/14/24 8:49:34 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/13/24 4:40:10 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Mona Chetan bought $5,699 worth of shares (2,500 units at $2.28), increasing direct ownership by 50% to 7,500 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      11/22/24 4:32:31 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Patel Mona Chetan bought $16,520 worth of shares (5,000 units at $3.30) (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      9/11/24 4:50:47 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

      Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

      6/24/24 7:29:10 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    SEC Filings

    See more
    • Envoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      5/1/25 4:44:23 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Envoy Medical Inc.

      10-Q - Envoy Medical, Inc. (0001840877) (Filer)

      5/1/25 4:24:34 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Envoy Medical Inc.

      DEFA14A - Envoy Medical, Inc. (0001840877) (Filer)

      4/18/25 4:19:07 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Financials

    Live finance-specific insights

    See more
    • Envoy Medical Reports on First Quarter 2025 Results

      Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

      5/1/25 4:30:00 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to

      3/31/25 9:15:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events

      WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous

      11/14/24 8:38:22 AM ET
      $COCH
      Industrial Specialties
      Health Care